Ranbaxy news from FierceBiotech
NewsDaiichi Sankyo and Ranbaxy - Billion-dollar deals
Who: Daiichi SankyoWith: RanbaxyWhat: $4.6B buyout Scoop: Takeda wasn't the only Japanese drugmaker to ink a billion-dollar deal. In a $4.6 billion deal, Daiichi Sanyko bought Indian powerhouse Read more...
Report: Pfizer makes counter-offer for Ranbaxy
Pfizer may be crashing Daiichi Sankyo's party. Business Standard is reporting that Pfizer is considering a counter-offer for Ranbaxy, India's largest drugmaker. The rumor comes on the heels of the Read more...
Daiichi Sankyo acquires Ranbaxy in $4.6B deal
Ranbaxy's drive to become a research-based drug developer and major manufacturer has led it straight into the Read more...
Merck turns to Ranbaxy for $100M R&D effort
India's Ranbaxy has flexed its research muscles once again, this time signing a five-year pact with Merck to develop new anti-infectives. Ranbaxy, which received an undisclosed upfront payment, says Read more...
India eyes R&D opportunities
India-based drugs have made a name for themselves as makers of copycat drugs. When a developer's lucrative drug goes off-patent, Indian companies are guaranteed to swoop in and make a less-expensive Read more...
Ranbaxy spins off R&D unit
Ranbaxy, one of India's largest drug makers and a dominant force in the generic drugs business, is spinning off its R&D unit that will develop new medicines. The move will allow the drugmaker to Read more...
SPOTLIGHT: India focuses on biosimilars
India sees a big future for itself in biogenerics. Wockhardt, Dr Reddy's Lab, Biocon, Sun Pharma, Shanta Biotech, Panacea Biotech and Ranbaxy Lab are all initiating programs Read more...
ALSO NOTED: Knopf tapped to run Acceleron; FDA clears Samaritan IND; Wockhardt in hunt for Par; and much more...
> Chutes & Ladders: Acceleron Pharma has named John L. Knopf, Ph.D., as its new CEO. Dr. Knopf, a founder of Acceleron, has served as the executive vice president of corporate Read more...
AstraZeneca, Pozen start Phase III combo drug trial
AstraZeneca and Pozen are starting Phase III trial of PN400, an experimental drug for arthritis pain that combines AstraZeneca's heartburn drug Nexium with the anti-inflammatory drug naproxen. In Read more...
ALSO NOTED: Medicines Company gets positive safety data; InterMune gains $10M payday; and much more...> The Medicines Company announced that three late-stage safety trials of Cleviprex, an experimental drug for severe high blood pressure, met their specified objectives. Release > InterMune has pocketed a $10 million milestone payment from its pact with Roche on an experimental hepatitis C therapy. Release > Genentech has agreed to pay an unspecified amount for … Read more... | Press ReleasesPRESS RELEASE: Ranbaxy's Q3 PAT Increases 48% Ranbaxy's Q3 PAT Increases 48% GLOBAL SALES AT USD 406 MN, UP BY 15% IN PRINCIPLE BOARD APPROVAL FOR R&D DEMERGER FOR DRUG DISCOVERY RESEARCH Gurgaon, Haryana, India - October 18, 2007 The Read more... PRESS RELEASE: Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP Ranbaxy One of Few Companies to Offer Both Suspension and Tablet Forms PRINCETON, N.J., Oct. 2 -- Read more... PRESS RELEASE: Canadian Court Favors Ranbaxy, Dismisses Pfizer's Application on Atrovastatin Patent CANADIAN FEDERAL COURT FAVOURS RANBAXY DISMISSES PFIZER'S APPLICATION ON ATORVASTATIN PATENT CA 2,220,455 Gurgaon, Haryana, India, Princeton, New Jersey, USA - September 13, 2007 Ranbaxy Read more... PRESS RELEASE: Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis Ranbaxy will benefit from the 180 day shared exclusivity on the product PRINCETON, N.J. -- Read more... |
Get more Ranbaxy coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets